Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer

NCT01138163 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG: Docetaxel plus bavituximab or placebo

Sponsor

Peregrine Pharmaceuticals